Home › Compare › PHASQ vs O

PHASQ vs O: Dividend Comparison 2026

PHASQ yields 200000000.00% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHASQ wins by $4.875657285131069e+59M in total portfolio value
10 years
PHASQ
PHASQ
● Live price
200000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875657285131069e+59M
Annual income
$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full PHASQ calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — PHASQ vs O

📍 PHASQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHASQO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHASQ + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PHASQ pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHASQ
Annual income on $10K today (after 15% tax)
$17,000,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, PHASQ beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHASQ + O for your $10,000?

PHASQ: 50%O: 50%
100% O50/50100% PHASQ
Portfolio after 10yr
$2.4378286425655345e+59M
Annual income
$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

PHASQ
No analyst data
Altman Z
-42.8
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHASQ buys
0
O buys
0
No recent congressional trades found for PHASQ or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHASQO
Forward yield200000000.00% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$4.875657285131069e+59M$34.2K ✓
Annual income after 10y$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$5,102.74
Total dividends collected$4.875656971401711e+59M$20.7K ✓
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: PHASQ vs O ($10,000, DRIP)

YearPHASQ PortfolioPHASQ Income/yrO PortfolioO Income/yrGap
1← crossover$20,000,010,700$20,000,000,000.00$10,818$608.16+$20000.00M → PHASQ
2$37,383,218,970,104,910$37,383,197,570,093,464.00$11,787$741.68+$37383218970.09M → PHASQ
3$65,303,942,472,059,150,000,000$65,303,902,472,014,860,000,000.00$12,946$911.00+$65303942472059152.00M → PHASQ
4$106,615,009,060,306,890,000,000,000,000$106,614,939,185,088,440,000,000,000,000.00$14,345$1,127.94+$1.0661500906030689e+23M → PHASQ
5$162,672,273,967,082,950,000,000,000,000,000,000$162,672,159,889,023,270,000,000,000,000,000,000.00$16,056$1,409.05+$1.6267227396708296e+29M → PHASQ
6$231,966,340,306,755,300,000,000,000,000,000,000,000,000$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00$18,171$1,777.83+$2.319663403067553e+35M → PHASQ
7$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00$20,820$2,268.21+$3.091381823051466e+41M → PHASQ
8$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00$24,188$2,929.90+$3.850317772522584e+47M → PHASQ
9$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$28,533$3,837.11+$4.481844117993459e+53M → PHASQ
10$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$34,235$5,102.74+$4.875657285131069e+59M → PHASQ

PHASQ vs O: Complete Analysis 2026

PHASQ — Stock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHASQ Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this PHASQ vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHASQ vs SCHDPHASQ vs JEPIPHASQ vs KOPHASQ vs MAINPHASQ vs STAGPHASQ vs ADCPHASQ vs NNNPHASQ vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.